BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 28752637)

  • 21. Fourteen-Year Anti-TNF Therapy in Crohn's Disease Patients: Clinical Characteristics and Predictive Factors.
    Osamura A; Suzuki Y
    Dig Dis Sci; 2018 Jan; 63(1):204-208. PubMed ID: 29209921
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Surgical Treatment in Childhood-onset Inflammatory Bowel Disease-A Nationwide Register-based Study of 4695 Incident Patients in Sweden 2002-2014.
    Nordenvall C; Rosvall O; Bottai M; Everhov ÅH; Malmborg P; Smedby KE; Ekbom A; Askling J; Ludvigsson JF; Myrelid P; Olén O
    J Crohns Colitis; 2018 Jan; 12(2):157-166. PubMed ID: 29029152
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SAFETY PROFILE OF ANTI-TNF THERAPY IN CROHN'S DISEASE MANAGEMENT: A BRAZILIAN SINGLE-CENTER DIRECT RETROSPECTIVE COMPARISON BETWEEN INFLIXIMAB AND ADALIMUMAB.
    Bau M; Zacharias P; Ribeiro DA; Boaron L; Steckert Filho A; Kotze PG
    Arq Gastroenterol; 2017 Dec; 54(4):328-332. PubMed ID: 28954043
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of infliximab with adalimumab in 827 biologic-naïve patients with Crohn's disease: a population-based Danish cohort study.
    Singh S; Andersen NN; Andersson M; Loftus EV; Jess T
    Aliment Pharmacol Ther; 2018 Mar; 47(5):596-604. PubMed ID: 29239001
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early Ileocecal Resection for Crohn's Disease Is Associated With Improved Long-term Outcomes Compared With Anti-Tumor Necrosis Factor Therapy: A Population-Based Cohort Study.
    Agrawal M; Ebert AC; Poulsen G; Ungaro RC; Faye AS; Jess T; Colombel JF; Allin KH
    Gastroenterology; 2023 Oct; 165(4):976-985.e3. PubMed ID: 37321356
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regional differences in anti-TNF-α therapy and surgery in the treatment of inflammatory bowel disease patients: a Norwegian nationwide cohort study.
    Lirhus SS; Høivik ML; Moum B; Melberg HO
    Scand J Gastroenterol; 2018 Aug; 53(8):952-957. PubMed ID: 30205699
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TNF inhibitor therapy and risk of breast cancer recurrence in patients with rheumatoid arthritis: a nationwide cohort study.
    Raaschou P; Frisell T; Askling J;
    Ann Rheum Dis; 2015 Dec; 74(12):2137-43. PubMed ID: 25107559
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience.
    Fréling E; Baumann C; Cuny JF; Bigard MA; Schmutz JL; Barbaud A; Peyrin-Biroulet L
    Am J Gastroenterol; 2015 Aug; 110(8):1186-96. PubMed ID: 26195181
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-Drug Antibodies, Drug Levels, Interleukin-6 and Soluble TNF Receptors in Rheumatoid Arthritis Patients during the First 6 Months of Treatment with Adalimumab or Infliximab: A Descriptive Cohort Study.
    Eng GP; Bouchelouche P; Bartels EM; Bliddal H; Bendtzen K; Stoltenberg M
    PLoS One; 2016; 11(9):e0162316. PubMed ID: 27606615
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients.
    Chaparro M; Barreiro-de Acosta M; Echarri A; Almendros R; Barrio J; Llao J; Gomollón F; Vera M; Cabriada JL; Guardiola J; Guerra I; Beltrán B; Roncero O; Busquets D; Taxonera C; Calvet X; Ferreiro-Iglesias R; Ollero Pena V; Bernardo D; Donday MG; Garre A; Godino A; Díaz A; Gisbert JP
    Dig Dis Sci; 2019 Mar; 64(3):846-854. PubMed ID: 30426297
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Colorectal cancer in Crohn's disease: a Scandinavian population-based cohort study.
    Olén O; Erichsen R; Sachs MC; Pedersen L; Halfvarson J; Askling J; Ekbom A; Sørensen HT; Ludvigsson JF
    Lancet Gastroenterol Hepatol; 2020 May; 5(5):475-484. PubMed ID: 32066530
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of the early use of immunomodulators or TNF antagonists on bowel damage and surgery in Crohn's disease.
    Safroneeva E; Vavricka SR; Fournier N; Pittet V; Peyrin-Biroulet L; Straumann A; Rogler G; Schoepfer AM;
    Aliment Pharmacol Ther; 2015 Oct; 42(8):977-89. PubMed ID: 26271358
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-TNF-alpha treatments and obstructive symptoms in Crohn's disease: a prospective study.
    Condino G; Calabrese E; Zorzi F; Onali S; Lolli E; De Biasio F; Ascolani M; Pallone F; Biancone L
    Dig Liver Dis; 2013 Mar; 45(3):258-62. PubMed ID: 23195667
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incidence of psoriasiform diseases secondary to tumour necrosis factor antagonists in patients with inflammatory bowel disease: a nationwide population-based cohort study.
    Bae JM; Lee HH; Lee BI; Lee KM; Eun SH; Cho ML; Kim JS; Park JM; Cho YS; Lee IS; Kim SW; Choi H; Choi MG
    Aliment Pharmacol Ther; 2018 Jul; 48(2):196-205. PubMed ID: 29869804
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term outcomes of patients with Crohn's disease who received infliximab or adalimumab as the first-line biologics.
    Inokuchi T; Takahashi S; Hiraoka S; Toyokawa T; Takagi S; Takemoto K; Miyaike J; Fujimoto T; Higashi R; Morito Y; Nawa T; Suzuki S; Nishimura M; Inoue M; Kato J; Okada H
    J Gastroenterol Hepatol; 2019 Aug; 34(8):1329-1336. PubMed ID: 30724387
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Concomitant therapy with methotrexate and anti-TNF-α in pediatric patients with refractory crohn's colitis: a case series.
    Absah I; Faubion WA
    Inflamm Bowel Dis; 2012 Aug; 18(8):1488-92. PubMed ID: 21882301
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bowel Damage as Assessed by the Lémann Index is Reversible on Anti-TNF Therapy for Crohn's Disease.
    Fiorino G; Bonifacio C; Allocca M; Repici A; Balzarini L; Malesci A; Peyrin-Biroulet L; Danese S
    J Crohns Colitis; 2015 Aug; 9(8):633-9. PubMed ID: 25958059
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness of anti-tumour necrosis factor-α therapy in Danish patients with inflammatory bowel diseases.
    Bank S; Andersen PS; Burisch J; Pedersen N; Roug S; Galsgaard J; Turino SY; Brodersen JB; Rashid S; Avlund S; Olesen TB; Green A; Hoffmann HJ; Thomsen MK; Thomsen VØ; Nexø BA; Vogel U; Andersen V
    Dan Med J; 2015 Mar; 62(3):. PubMed ID: 25748864
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study.
    Bouhnik Y; Carbonnel F; Laharie D; Stefanescu C; Hébuterne X; Abitbol V; Nachury M; Brixi H; Bourreille A; Picon L; Bourrier A; Allez M; Peyrin-Biroulet L; Moreau J; Savoye G; Fumery M; Nancey S; Roblin X; Altwegg R; Bouguen G; Bommelaer G; Danese S; Louis E; Zappa M; Mary JY;
    Gut; 2018 Jan; 67(1):53-60. PubMed ID: 28119352
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical effectiveness of golimumab in Crohn's disease: an observational study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG).
    Rundquist S; Eriksson C; Nilsson L; Angelison L; Jäghult S; Björk J; Grip O; Hjortswang H; Strid H; Karlén P; Montgomery S; Halfvarson J
    Scand J Gastroenterol; 2018; 53(10-11):1257-1263. PubMed ID: 30353751
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.